This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brell, M. Articles by Graus, F. Search for Related Content PubMed PubMed Citation Articles by Brell, M. Articles by Graus, F.

Prognostic Significance of O⁶-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas

Authors' Affiliations: Institut d'Investigació Biomèdica de Bellvitge, ¹ Hospital Universitari de Bellvitge, ² Institut Català d'Oncologia, ³ Institut de Neuropatología, ⁴ Universitat de Barcelona, Departament d'Infermeria Fonamental, L'Hospitalet de Llobregat, and ⁵ Institut d'Investigacions Biomèdiques August Pi i Sunyer, Hospital Clínic de Barcelona, Barcelona, Spain

Requests for reprints: Avelina Tortosa, Universitat de Barcelona, Escola Universitària d'Infermeria, Campus de Bellvitge, C/ Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain. Phone: 34-934024221; Fax: 34-934024216; E-mail: atortosa{at}ub.edu.

Purpose: Anaplastic gliomas constitute a heterogeneous group of tumors with different therapeutic responses to adjuvant chemotherapy with alkylating agents. O⁶-Methylguanine-DNA methyltransferase (MGMT), a DNA repair protein, is one of the implicated factors in glioma chemoresistance.The prognostic value of MGMT remains controversial due in part to the fact that previous published studies included heterogeneous groups of patients with different tumor grades. The aim of this study was to evaluate the prognostic significance of MGMT in patients with anaplastic glioma.

Experimental Design: Ninety-three patients with anaplastic glioma were analyzed for MGMT protein expression by immunohistochemistry. In addition, for those patients from whom a good yield of DNA was obtained (n = 40), MGMT promoter methylation profile was analyzed by methylation-specific PCR. MGMT prognostic significance was evaluated together with other well-known prognostic factors.

Results: Fifty-one tumors (54.8%) showed nuclear staining of MGMT. There was a trend towards longer overall survival for those patients with negative MGMT immunostaining (hazard ratio, 1.66; P = 0.066). In a secondary analysis including those patients who actually received chemotherapy (n = 72), the absence of MGMT expression was independently associated with better survival (hazard ratio, 2.12; P = 0.027). MGMT promoter methylation was observed in 50% of the analyzed tumors. No statistical correlation between MGMT expression and MGMT promoter hypermethylation was observed.

Conclusions: Unlike previous studies, we did not find a correlation between MGMT promoter methylation and survival. However, we observed a correlation between MGMT protein expression and survival in those patients who received chemotherapy thus suggesting that the absence of MGMT expression is a positive predictive marker in patients with anaplastic glioma.

This article has been cited by other articles:

				M. Nagane, K. Kobayashi, A. Ohnishi, S. Shimizu, and Y. Shiokawa Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Protein Expression in Patients with Recurrent Glioblastoma Treated with Temozolomide Jpn. J. Clin. Oncol., December 21, 2007; (2007) hym132v1. [Abstract] [Full Text] [PDF]

				I. Lavon, D. Fuchs, D. Zrihan, G. Efroni, B. Zelikovitch, Y. Fellig, and T. Siegal Novel Mechanism whereby Nuclear Factor {kappa}B Mediates DNA Damage Repair through Regulation of O6-Methylguanine-DNA-Methyltransferase Cancer Res., September 15, 2007; 67(18): 8952 - 8959. [Abstract] [Full Text] [PDF]

				L. M. Wagner, R. E. McLendon, K. J. Yoon, B. D. Weiss, C. A. Billups, and M. K. Danks Targeting Methylguanine-DNA Methyltransferase in the Treatment of Neuroblastoma Clin. Cancer Res., September 15, 2007; 13(18): 5418 - 5425. [Abstract] [Full Text] [PDF]

				R. Stupp, M. E. Hegi, M. R. Gilbert, and A. Chakravarti Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions J. Clin. Oncol., September 10, 2007; 25(26): 4127 - 4136. [Abstract] [Full Text] [PDF]

				M. Eoli, F. Menghi, M. G. Bruzzone, T. De Simone, L. Valletta, B. Pollo, L. Bissola, A. Silvani, D. Bianchessi, L. D'Incerti, et al. Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival Clin. Cancer Res., May 1, 2007; 13(9): 2606 - 2613. [Abstract] [Full Text] [PDF]

				O. L. Chinot, M. Barrie, S. Fuentes, N. Eudes, S. Lancelot, P. Metellus, X. Muracciole, D. Braguer, L. Ouafik, P.-M. Martin, et al. Correlation Between O6-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant Temozolomide J. Clin. Oncol., April 20, 2007; 25(12): 1470 - 1475. [Abstract] [Full Text] [PDF]

				I. Lavon, D. Zrihan, B. Zelikovitch, Y. Fellig, D. Fuchs, D. Soffer, and T. Siegal Longitudinal Assessment of Genetic and Epigenetic Markers in Oligodendrogliomas Clin. Cancer Res., March 1, 2007; 13(5): 1429 - 1437. [Abstract] [Full Text] [PDF]

				A. A. Brandes, A. Tosoni, G. Cavallo, M. Reni, E. Franceschi, L. Bonaldi, R. Bertorelle, M. Gardiman, C. Ghimenton, P. Iuzzolino, et al. Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study J. Clin. Oncol., October 10, 2006; 24(29): 4746 - 4753. [Abstract] [Full Text] [PDF]

				J. A. Maxwell, S. P. Johnson, J. A. Quinn, R. E. McLendon, F. Ali-Osman, A. H. Friedman, J. E. Herndon II, K. Bierau, J. Bigley, D. D. Bigner, et al. Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol. Cancer Ther., October 1, 2006; 5(10): 2531 - 2539. [Abstract] [Full Text] [PDF]

				D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner Recent Advances in the Treatment of Malignant Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265. [Abstract] [Full Text] [PDF]